Source-grounded facts extracted from Streamex Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Mitchell Young Williams was appointed as Director at Streamex Corp..
“On April 28, 2026, the board of directors (the “Board”) of Streamex Corp. (the “Company”) appointed Mr. Mitchell Young Williams, the Company’s Chief Investment Officer, to serve as a non-independent director of the Board”
Streamex Corp. terminated Yorkville Debentures with YA II PN, LTD. valued at aggregate cash payoff amount of $38,902,740 (effective 2026-02-06).
“the Company pre-paid the remaining amounts due under the Yorkville Debentures for an aggregate cash payoff amount of $38,902,740”
Streamex Corp. terminated Standby Equity Purchase Agreement with YA II PN, Ltd. (Yorkville) (effective 2026-01-22).
“On January 22, 2026, Streamex Corp. delivered a notice terminating the Standby Equity Purchase Agreement (the “SEPA”), dated July 7, 2025, with YA II PN, Ltd. (“Yorkville”), effective five trading days after the notice date.”
Streamex Corp. entered into Underwriting Agreement with Needham & Company, LLC (effective 2026-01-22).
“On January 22, 2026, Streamex Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Needham & Company, LLC, as representative of the several underwriters (the “Underwriters”), pursuant to which the Company agreed to sell and issue to the Underwriters an aggregate of 11,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) in a public offering (the “Offering”).”
Streamex Corp. entered into Second Convertible Debenture (second tranche) with YA II PN, LTD. valued at Issuance of second tranche convertible debenture with principal amount of $25,000,000; conversion pr (effective 2025-12-17).
“greement with YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville” or the “Investor”), for the issuance and sale by the Company of convertible debentures (the “Convertible Debentures,” each, a “Convertible Debenture”), which Convertible Debentures will be convertible into shares of the”
Streamex Corp. amended Secured Convertible Debenture Purchase Agreement Amendment No. 4 with YA II PN, LTD. valued at Amendment to Secured Convertible Debenture Purchase Agreement; $25,000,000 second tranche convertibl (effective 2025-12-17).
“Further to this, on December 17, 2025, the Company entered into a certain Amendment No. 4 to the Debenture Purchase Agreement (the “Fourth Amendment”) with Yorkville.”
Streamex Corp. issued convertible note to YA II PN, LTD. (Yorkville) for principal amount of $25,000,000.
“on December 17, 2025 (the "Second Closing Date"), the Company issued the second tranche of Convertible Debenture to Yorkville with a principal amount of $25,000,000”
Streamex Corp. incurred convertible notes of $25,000,000 with YA II PN, LTD. at 4.00% per annum, which will increase to 18.00% per annum upon the occurrence of maturing December 17, 2027.
“on December 17, 2025 (the “Second Closing Date”), the Company issued the second tranche of Convertible Debenture to Yorkville with a principal amount of $25,000,000 (the “Second Convertible Debenture”), on similar terms as the initial tranche of Convertible Debenture to Yorkville, dated November 4, 2025, as disclosed in our Prior Form 8-Ks.”
Streamex Corp. entered into Share Purchase Agreement with Terra Capital Natural Resources Fund Pty Ltd. valued at US$12,218,751.00 (effective 2025-12-11).
“On December 11, 2025, Streamex Corp. (the “Company”) entered into a Share Purchase Agreement (the “Purchase Agreement”) with Terra Capital Natural Resources Fund Pty Ltd. (“Purchaser”) pursuant to which the Company acquired a 9.9% equity interest in Empress Royalty Corp.”
Streamex Corp. issued 2,443,750 shares of Common Stock of common stock to Terra Capital Natural Resources Fund Pty Ltd. for 12,671,297 shares of Empress common stock.
“the Company issued 2,443,750 shares of Common Stock to Purchaser in exchange for 12,671,297 shares of Empress common stock held by Purchaser.”
Streamex Corp.: Company filed the Eleventh Amendment to its Amended and Restated Certificate of Incorporation to provide for a classified Board divided into three classes (effective 2025-11-19).
“On November 19, 2025 (the “Effective Date”) , the Company filed the Eleventh Amendment (the “Charter Amendment”) to the Company’s Amended and Restated Certificate of Incorporation with the Delaware Secretary of State, which became effective upon filing . The Charter Amendment provides for a classified Board, with the Board divided into three classes, pursuant to prior authorization of the Board and the requisite stockholders of the Company as more fully described in the Company’s definitive proxy statement filed with the SEC on August 4, 2025, as amended on August 15, 2025, September 2, 2025 and September 3, 2025 and the Company’s Current Report on Form 8-K filed with the SEC on September 5, 2025.”
Streamex Corp. issued convertible note to YA II PN, LTD. for $25,000,000 principal amount.
“the Company issued an initial tranche of Convertible Debenture to Yorkville with a principal amount of $25,000,000 (the "First Convertible Debenture").”
Streamex Corp. incurred convertible notes of $25,000,000 with YA II PN, LTD. at 4.00% per annum, increasing to 18.00% per annum upon an event of default maturing November 4, 2027.
“Further to this, on November 4, 2025 (the “First Closing Date”), the Company issued an initial tranche of Convertible Debenture to Yorkville with a principal amount of $25,000,000 (the “First Convertible Debenture”). The First Convertible Debenture will mature on November 4, 2027, and will accrue interest at the rate of 4.00% per annum, which will increase to 18.00% per annum upon the occurrence of an event of default, until such event of default is cured.”
Streamex Corp. issued convertible note to YA II PN, LTD. for $25,000,000 principal amount.
“the Company will issue to Yorkville a Convertible Debenture in the principal amount of $25,000,000”
Streamex Corp.: Amended certificate of incorporation to change company name from BioSig Technologies, Inc. to Streamex Corp (effective 2025-09-10).
“On September 10, 2025, BioSig Technologies, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect a change in the name of the Company from “BioSig Technologies, Inc.” to “Streamex Corp.” (the “Name Change”).”
Streamex Corp.: Approved and filed the Ninth Certificate of Amendment to increase authorized common shares from 200,000,000 to 500,000,000 (effective 2025-09-05).
“The Company filed the Ninth Certificate of Amendment, which was effective upon filing, with the Secretary of State of the State of Delaware on September 5, 2025.”
Streamex Corp.: Filed Special Voting Certificate of Designation with the Delaware Secretary of State to establish Special Voting Preferred Stock (effective 2025-05-28).
“On and effective May 28, 2025, the Company filed the Special Voting Certificate of Designation with the Secretary of State of the State of Delaware to establish the Special Voting Preferred Stock.”
Frederick D. Hrkac resigned as Director at Streamex Corp..
“Frederick D. Hrkac resigned from the Board”
Morgan Lekstrom was appointed as Director at Streamex Corp..
“Mr. McPhie and Mr. Lekstrom were appointed as new directors of the Board.”
Morgan Lekstrom was appointed as Chairman of the Board at Streamex Corp..
“Morgan Lekstrom, co-founder and Chairman of Streamex, was appointed as the Chairman of the Board.”
Henry McPhie was appointed as Director at Streamex Corp..
“Mr. McPhie and Mr. Lekstrom were appointed as new directors of the Board.”
Henry McPhie was appointed as Chief Executive Officer at Streamex Corp..
“Henry McPhie, co-founder and Chief Executive Officer of Streamex, was appointed the Company’s new Chief Executive Officer.”
Anthony Amato resigned as Chief Executive Officer, President and Chairman of the Board at Streamex Corp..
“Anthony Amato, the Company’s Chief Executive Officer, President and Chairman of the Board of Directors of the Company (the “Board”), resigned as Chief Executive Officer, President and Chairman of the Board”
Streamex Corp.: Company agrees to file Special Voting Certificate of Designation to establish Special Voting Preferred Stock.
“Pursuant to the Share Purchase Agreement, the Company has agreed to file the Special Voting Certificate of Designation with the Secretary of State of the State of Delaware to establish the Special Voting Preferred Stock.”
Anthony Amato resigned as other_named_officer at Streamex Corp..
“In connection with Mr. Amato’s resignation pursuant to the Share Purchase Agreement, the Company and Mr. Amato expect to enter into (i) a First Amendment to the Executive Employment Agreement (the “First Amendment”) and (ii) a letter agreement (the “Right to Place”).”
Streamex Corp. engaged CBIZ CPAs P.C. as its auditor.
“Also on April 30, 2025, the Registrant, with the approval of the Audit Committee of the Registrant’s Board of Directors, engaged CBIZ CPAs P.C. as the Registrant’s independent registered public accounting firm.”
Marcum LLP resigned as auditor of Streamex Corp..
“On April 30, 2025, Marcum informed BioSig Technologies, Inc. (the “Registrant”) that Marcum resigned as the Registrant’s independent registered public accounting firm.”
Streamex Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“April 11, 2025, BioSig Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between February 27, 2025, through April 10, 2025, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calenda”
Anthony Amato was appointed as Chairman at Streamex Corp..
“On September 11, 2024, pursuant to Section 5.2 of the Company’s bylaws, the Board appointed the Company’s chief executive officer, Mr. Anthony Amato, as Chairman.”
Kenneth L. Londoner resigned as Chairman at Streamex Corp..
“As previously announced on February 27, 2024, Kenneth L. Londoner, the former chairperson (“Chairman”) of the Board of Directors (the “Board”) of BioSig Technologies, Inc. (the “Company”) resigned from the Company.”
Ferdinand Groenewald was appointed as interim chief financial officer, principal accounting officer and vice president of finance at Streamex Corp..
“Mr. Groenewald will serve as the Company’s interim chief financial officer, principal accounting officer and vice president of finance.”
Frederick D. Hrkac resigned as acting chief financial officer and principal accounting officer at Streamex Corp..
“On June 5, 2024, Mr. Frederick D. Hrkac resigned as acting chief financial officer and principal accounting officer of BioSig Technologies, Inc. (“BioSig” or “Company”) effective as of the same date.”
Streamex Corp. received a nasdaq noncompliance notice notice regarding other (rules 5550(a)(2), 5810(c)(3)(A)(2)).
“March 5, 2024, stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second 180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company’s common stock unless the Company requested an appeal of this”
Streamex Corp. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
“May 6, 2024, the Company received a letter from the Staff stating that the Company has regained compliance with the bid price requirements in Listing Rule 5550(a)(2) because the bid price of the common stock closed at or above $1.00 per share for a period of 20 consecutive business days, from April 8, 2024 to May 3, 2024. The Company remains, however, non-compliant with The Nasdaq Stock Market’s market value of listed securities, public shell, and independent board and board committee requirements. Therefore, the May 7, 2024, hearing will be held as scheduled. SIGNATURES Pursuant to the requir”
Chris Baer was appointed as Director at Streamex Corp..
“As previously announced on May 2, 2024, the Board appointed Mr. Chris Baer as a director on the Board.”
Donald F. Browne was appointed as Director at Streamex Corp..
“On May 3, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed Messrs. Steven E. Abelman and Donald F. Browne as directors on the Board.”
Steven E. Abelman was appointed as Director at Streamex Corp..
“On May 3, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed Messrs. Steven E. Abelman and Donald F. Browne as directors on the Board.”
Mr. Hrkac resigned as Director and Acting Chief Financial Officer at Streamex Corp..
“In connection with the appointment of Mr. Amato, Mr. Hrkac tendered his resignation as president and principal executive officer effective as of the same date, however, will continue to serve as a director and acting chief financial officer.”
Anthony Amato was appointed as Chief Executive Officer at Streamex Corp..
“On April 30, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed former advisory board member and consultant, Anthony Amato as a director, president, chief executive officer and principal executive officer, effective immediately.”
Chris Baer was appointed as director at Streamex Corp..
“On May 2, 2024, the board of directors of BioSig Technologies, Inc. (the “Board”) appointed Mr. Chris Baer as a director on the Board.”
Streamex Corp. received a nasdaq delisting notice notice regarding board independence (rules 5101, 5605).
“March 12, 2024, the Company received a letter from the Staff stating that based upon the Staff’s review of the Company and pursuant to Listing Rule 5101, the Staff believes that the Company no longer has an operating business and is a “public shell,” and that the continued listing of its securities is no longer warranted, in view of the following: ● On February 5, 2024, the Company disclosed in a Form 8-K that the Company commenced a workforce reduction consisting of 16 employees including the Chief Operating Officer and the Chief Commercial Officer; ● On February 21, 2024, the Company disc”
Streamex Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(2)).
“March 5, 2024, BioSig Technologies, Inc. (the “Company”) received a letter from the Listing Qualifications Department of Nasdaq (the “Staff”) stating that the Company has not regained compliance with Listing Rule 5550(a)(2) because the Company’s common stock did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market, and the Company is not eligible for a second 180 day cure period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capit”
Streamex Corp. entered into Promissory Note with an investor valued at $500,000 (effective 2024-03-07).
“On March 7, 2024, BioSig Technologies Inc. (the “Company”) issued a Promissory Note (the “Note”) to an investor for $500,000.”
Streamex Corp. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5810(c)(3)(A)(2)).
“March 5, 2024, the Company received a letter from the Listing Qualifications Department of Nasdaq stating that the Company has not regained compliance with the Rule and is not eligible for a second 180 day period under Rule 5810(c)(3)(A)(2) because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market, and that accordingly, Nasdaq would delist the Company’s common stock unless the Company requested an appeal of this determination. On March 11, 2024, the Company submitted a request for a hearing before the Nasdaq H”
Frederick D. Hrkac was appointed as President and Principal Executive Officer at Streamex Corp..
“On February 27, 2024, the Board appointed former director, Frederick D. Hrkac as a director, president and principal executive officer of the Company, effective as of February 27, 2024 (the “Effective Date”), to serve for a term expiring at the next annual meeting of the Company’s stockholders or until his successor is duly elected and qualified, or his earlier death, resignation or removal.”
Kenneth L. Londoner resigned as Chief Executive Officer and Executive Chairman at Streamex Corp..
“Kenneth L. Londoner resigned from his positions as director, executive chairman and chief executive officer of BioSig Technologies, Inc. (the “ Company ”) and from any and all committees, offices, appointments, designations, responsibilities or other capacities related to the Company or any of its subsidiaries, effective as of the Effective Date.”
Frederick D. Hrkac resigned as director at Streamex Corp..
“On February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the same date.”
James L. Klein resigned as director at Streamex Corp..
“On February 20, 2024, James L. Klein and Frederick D. Hrkac resigned from their positions as directors of the Company, effective as of the same date.”
James J. Barry resigned as director at Streamex Corp..
“On February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors of the Company, effective as of the same date.”
Patrick J. Gallagher resigned as director at Streamex Corp..
“On February 19, 2024, David Weild IV, Donald E. Foley, Patrick J. Gallagher and James J. Barry, resigned from their positions as directors of the Company, effective as of the same date.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.